Evidence map›Paper›PMID 34767577›Full record

ArticlePloS one2021

Treatment selection using prototyping in latent-space with application to depression treatment.

Akiva Kleinerman, Ariel Rosenfeld, David Benrimoh, Robert Fratila, Caitrin Armstrong, Joseph Mehltretter, Eliyahu Shneider, Amit Yaniv-Rosenfeld, Jordan Karp, Charles F Reynolds and 2 more

Abstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Frontiers in psychiatry · 2024
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Akiva KleinermanBar-Ilan University, Ramat-Gan, Israel.ORCID 0000-0003-2056-9694
Ariel RosenfeldBar-Ilan University, Ramat-Gan, Israel.
David BenrimohMcGill University, Montreal, Canada.
Robert FratilaAifred Health, Montreal, Canada.ORCID 0000-0002-3292-6233
Caitrin ArmstrongAifred Health, Montreal, Canada.
Joseph MehltretterAifred Health, Montreal, Canada.
Eliyahu ShneiderBar-Ilan University, Ramat-Gan, Israel.
Amit Yaniv-RosenfeldShalvata Mental Health Center, Hod Hasharon, Israel.
Jordan KarpUniversity of Arizona, Tucson, Arizona, United States of America.
Charles F ReynoldsUniversity of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
Gustavo TureckiAifred Health, Montreal, Canada.
Adam KapelnerQueens College, New York City, NY, United States of America.ORCID 0000-0001-5985-6792

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Machine-assisted treatment selection commonly follows one of two paradigms: a fully personalized paradigm which ignores any possible clustering of patients; or a sub-grouping paradigm which ignores personal differences within the identified groups. While both paradigms have shown promising results, each of them suffers from important limitations. In this article, we propose a novel deep learning-based treatment selection approach that is shown to strike a balance between the two paradigms using latent-space prototyping. Our approach is specifically tailored for domains in which effective prototypes and sub-groups of patients are assumed to exist, but groupings relevant to the training objective are not observable in the non-latent space. In an extensive evaluation, using both synthetic and Major Depressive Disorder (MDD) real-world clinical data describing 4754 MDD patients from clinical trials for depression treatment, we show that our approach favorably compares with state-of-the-art approaches. Specifically, the model produced an 8% absolute and 23% relative improvement over random treatment allocation. This is potentially clinically significant, given the large number of patients with MDD. Therefore, the model can bring about a much desired leap forward in the way depression is treated today.

Indexed as

Deep LearningAntidepressive AgentsArea Under CurveClinical Decision-MakingClinical Trials as TopicDepressionDrug Therapy, CombinationHumansMajor Depressive DisorderPrecision MedicineRemission InductionTreatment OutcomeAntidepressive Agents

Identifiers

PMID34767577
PMCPMC8589171

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.